An eccentric calpain, CAPN3/p94/calpain-3

被引:75
作者
Ono, Yasuko [1 ]
Ojima, Koichi [1 ,2 ]
Shinkai-Ouchi, Fumiko [1 ]
Hata, Shoji [1 ]
Sorimachi, Hiroyuki [1 ]
机构
[1] Tokyo Metropolitan Inst Med Sci IGAKUKEN, Dept Adv Sci Biomol, Calpain Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan
[2] NARO Inst Livestock & Grassland Sci, Anim Prod Res Div, Ikenodai 2, Tsukuba, Ibaraki 3050901, Japan
关键词
Calpain; Autolysis; Muscular dystrophy; Molecular evolution; Structure-activity relationship; Substrate; GIRDLE MUSCULAR-DYSTROPHY; MUSCLE-SPECIFIC CALPAIN; ACTIVATED NEUTRAL PROTEASE; HUMAN SKELETAL-MUSCLE; C-TERMINAL TITIN; KAPPA-B PATHWAY; RESTORE PROTEOLYTIC ACTIVITY; CRYSTAL-STRUCTURE; EF-HAND; GENE-EXPRESSION;
D O I
10.1016/j.biochi.2015.09.010
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Calpains are Ca2+-regulated proteolytic enzymes that are involved in a variety of biological phenomena. Calpains process substrates by limited proteolysis to modulate various protein functions in the cell, and are thus called "modulator proteases." CAPN3, previously called p94 or calpain-3, has unique features that are not found in any of the other 14 human calpains, or even in other proteases. For instance, CAPN3 undergoes extremely rapid and exhaustive autodegradation. CAPN3 is also the first (and so far, the only) intracellular enzyme found to depend on Na+ for its activation. CAPN3 has both proteolytic and non-proteolytic functions. It has the interesting distinction of being the only protease, other than a few virus proteases, with the ability to regain protease function after its autolytic dissociation; this occurs through a process known as intermolecular complementation (iMOC). Gene mutations causing CAPN3 defects are responsible for limb-girdle muscular dystrophy type 2A (LGMD2A). Unusual characteristics of CAPN3 have fascinated researchers, but have also hampered conventional biochemical analysis. In this review, we describe significant findings about CAPN3 from its discovery to the present, and suggest promising avenues for future CAPN3 research. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:169 / 187
页数:19
相关论文
共 262 条
[1]   The M-band: an elastic web that crosslinks thick filaments in the center of the sarcomere [J].
Agarkova, I ;
Perriard, JC .
TRENDS IN CELL BIOLOGY, 2005, 15 (09) :477-485
[2]   Adults with eosinophilic myositis and calpain-3 mutations [J].
Amato, Anthony A. .
NEUROLOGY, 2008, 70 (09) :730-731
[3]   Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies) [J].
Anderson, LVB ;
Harrison, RM ;
Pogue, R ;
Vafiadaki, E ;
Pollitt, C ;
Davison, K ;
Moss, JA ;
Keers, S ;
Pyle, A ;
Shaw, PJ ;
Mahjneh, I ;
Argov, Z ;
Greenberg, CR ;
Wrogemann, K ;
Bertorini, T ;
Goebel, HH ;
Beckmann, JS ;
Bashir, R ;
Bushby, KMD .
NEUROMUSCULAR DISORDERS, 2000, 10 (08) :553-559
[4]   Disruption of the mouse μ-calpain gene reveals an essential role in platelet function [J].
Azam, M ;
Andrabi, SS ;
Sahr, KE ;
Kamath, L ;
Kuliopulos, A ;
Chishti, AH .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (06) :2213-2220
[5]  
Azuma M, 2000, CURR EYE RES, V21, P710, DOI 10.1076/0271-3683(200009)21:3
[6]  
1-R
[7]  
FT710
[8]   Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IκBα/NF-κB pathway in limb-girdle muscular dystrophy type 2A [J].
Baghdiguian, S ;
Martin, M ;
Richard, I ;
Pons, F ;
Astier, C ;
Bourg, N ;
Hay, RT ;
Chemaly, R ;
Halaby, G ;
Loiselet, J ;
Anderson, LVB ;
de Munain, AL ;
Fardeau, M ;
Mangeat, P ;
Beckmann, JS ;
Lefranc, G .
NATURE MEDICINE, 1999, 5 (05) :503-511
[9]   Variation at the Calpain 3 gene is associated with meat tenderness in zebu and composite breeds of cattle [J].
Barendse, William ;
Harrison, Blair E. ;
Bunch, Rowan J. ;
Thomas, Merle B. .
BMC GENETICS, 2008, 9 (1)
[10]   Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A [J].
Bartoli, M ;
Roudaut, C ;
Martin, S ;
Fougerousse, F ;
Suel, L ;
Poupiot, J ;
Gicquel, E ;
Noulet, F ;
Danos, O ;
Richard, I .
MOLECULAR THERAPY, 2006, 13 (02) :250-259